MedTrace Logo

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

NCT01039701 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2010-08-11

No results posted yet for this study

Summary

The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.

Conditions

  • Mild to Moderate Alzheimer's Disease

Interventions

DRUG

AZD1446

capsules, oral, 3 times daily

DRUG

Placebo

capsules, oral, 3 times daily, 4 weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Czechia
  • Hungary
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01039701 on ClinicalTrials.gov